FOLH1 and Familial prostate cancer: The detection and staging of prostate cancer (PCa) dramatically improved over the last decade due to wide introduction into the clinical practice of prostate-specific membrane antigen (PSMA)-targeting agents based on Glu-urea-Lys binding moiety.